$23.45
Exelixis (EXEL) is a leading biotechnology business based in the US. It opened the day at $23.09 after a previous close of $22.96. During the day the price has varied from a low of $22.80 to a high of $23.47. The latest price was $23.45 (25 minute delay). Exelixis is listed on the NASDAQ and employs 1,310 staff. All prices are listed in US Dollars.
Our top picks for where to buy Exelixis stock
How to buy Exelixis stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – EXEL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Exelixis stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Exelixis stock price (NASDAQ: EXEL)
Use our graph to track the performance of EXEL stocks over time.Exelixis shares at a glance
Open | $23.09 |
---|---|
High | $23.47 |
Low | $22.80 |
Close | $23.45 |
Previous close | $22.96 |
Change | $0.49 |
Change % | 2.1341% |
Volume | 1,136,710 |
52-week range | $18.64 - $24.34 |
---|---|
50-day moving average | $21.78 |
200-day moving average | $22.07 |
Wall St. target price | $26.55 |
PE ratio | 34.7692 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.65 |
Is it a good time to buy Exelixis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Exelixis price performance over time
Historical closes compared with the close of $23.45 from 2024-07-25
1 week (2024-07-19) | 3.76% |
---|---|
1 month (2024-06-26) | 4.78% |
3 months (2024-04-26) | -1.05% |
6 months (2024-01-26) | 6.01% |
1 year (2023-07-26) | 18.31% |
---|---|
2 years (2022-07-26) | 9.94% |
3 years (2021-07-26) | 42.04% |
5 years (2019-07-26) | 12.74% |
Is Exelixis stock undervalued or overvalued?
Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Exelixis's P/E ratio
Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Exelixis shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Exelixis's PEG ratio
Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6856. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Exelixis's EBITDA
Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $229.6 million.
The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.
Exelixis financials
Revenue TTM | $1.8 billion |
---|---|
Operating margin TTM | 14.65% |
Gross profit TTM | $1.6 billion |
Return on assets TTM | 4.3% |
Return on equity TTM | 8.76% |
Profit margin | 11.1% |
Book value | $7.21 |
Market Capitalization | $6.6 billion |
TTM: trailing 12 months
Exelixis share dividends
We're not expecting Exelixis to pay a dividend over the next 12 months.
Exelixis share price volatility
Over the last 12 months, Exelixis's shares have ranged in value from as little as $18.64 up to $24.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 0.543. This would suggest that Exelixis's shares are less volatile than average (for this exchange).
Exelixis overview
Exelixis, Inc. , an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.
Frequently asked questions
nullWhat percentage of Exelixis is owned by insiders or institutions?
Currently 2.199% of Exelixis shares are held by insiders and 88.772% by institutions. How many people work for Exelixis?
Latest data suggests 1,310 work at Exelixis. When does the fiscal year end for Exelixis?
Exelixis's fiscal year ends in December. Where is Exelixis based?
Exelixis's address is: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 What is Exelixis's ISIN number?
Exelixis's international securities identification number is: US30161Q1040 What is Exelixis's CUSIP number?
Exelixis's Committee on Uniform Securities Identification Procedures number is: 30161Q104
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question